scispace - formally typeset
Journal ArticleDOI

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

TLDR
A recombinant human antibody to envelope glycoprotein gp120 was generated and used to show that primary isolates are not refractory to antibody neutralization, implying the conservation of a structural feature on gp120, which could be important in vaccine design.
Abstract
The ability of antibodies to neutralize diverse primary isolates of human immunodeficiency virus-type 1 in vitro has been questioned, with implications for the likely efficacy of vaccines. A recombinant human antibody to envelope glycoprotein gp120 was generated and used to show that primary isolates are not refractory to antibody neutralization. The recombinant antibody neutralized more than 75 percent of the primary isolates tested at concentrations that could be achieved by passive immunization, for example, to interrupt maternal-fetal transmission of virus. The broad specificity and efficacy of the antibody implies the conservation of a structural feature on gp120, which could be important in vaccine design.

read more

Citations
More filters
Journal ArticleDOI

The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates

TL;DR: The ability of various members of the chemokine receptor family to support the early stages of HIV-1 infection helps to explain viral tropism and beta-chemokine inhibition of primary HIV- 1 isolates.
Journal ArticleDOI

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

TL;DR: Three broadly neutralizing antibodies are identified, isolated from an HIV-1–infected individual, that exhibited great breadth and potency of neutralization and were specific for the co-receptor CD4-binding site of the glycoprotein 120 (gp120), part of the viral Env spike.
Journal ArticleDOI

Mechanisms of viral membrane fusion and its inhibition

TL;DR: The fusion mechanism involves a transient conformational species that can be targeted by therapeutic strategies and is likely utilized by a wide variety of enveloped viruses for which similar therapeutic interventions should be possible.
Journal ArticleDOI

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

TL;DR: Human monoclonal antibody 2G12 to the gp120 surface glycoprotein of human immunodeficiency virus type 1 (HIV-1) potently and broadly neutralizes primary and T-cell line-adapted clade B strains of HIV-1 and inhibits syncytium formation in the AA-2 cell line.
References
More filters
Journal ArticleDOI

Assembly of combinatorial antibody libraries on phage surfaces: the gene III site.

TL;DR: A phagemid system was developed for the monovalent display of combinatorial antibody Fab libraries on the surface of filamentous phage M13, and may replace current antibody cloning techniques.
Journal ArticleDOI

Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes

TL;DR: Heteroduplex mobility analysis provides a tool to expedite epidemiological investigations by assisting in the classification of HIV and is readily applicable to the screening and characterization of other infectious agents and cellular genes.
Journal ArticleDOI

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.

TL;DR: A panel of human monoclonal antibody Fab fragments has been generated against the surface glycoprotein gp120 of type 1 human immunodeficiency virus (HIV) by antigen selection from a random combinatorial library expressed on the surface of filamentous phage.
Journal ArticleDOI

A versatile in vivo and in vitro eukaryotic expression vector for protein engineering

TL;DR: The pSG5 vector as mentioned in this paper was constructed by combining the eukaryotic expression vector, pKCR2, and the high copy plasmid vector Bluescribe Ml3+ (Stratagene).
Journal ArticleDOI

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160

TL;DR: It is demonstrated that recombinant gp120, formulated in an adjuvant approved for human use, can elicit protective immunity against a homologous strain of HIV-1.
Related Papers (5)